FHTX Q4 2024 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-50.5% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$24M-840.5% margin

Net Income

-$20M-682.9% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

-63.4%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$284M

Total Liabilities

$330M

Stockholders' Equity

-$46M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$6M	-50.5%
Gross Profit	$3M	$5M	-41.9%
Operating Income	-$24M	-$25M	+5.7%
Net Income	-$20M	-$24M	+19.1%